Silencing TGF-beta1 and Cox2 using siRNA delivered in combination with immune checkpoint inhibitors to treat cancer

By silencing TGF-beta1 and Cox2 using siRNA delivered in combination with immune checkpoint inhibitors, the efficacy of cancer treatment is enhanced by increasing T cell entry and immune response against tumors, addressing the limited effectiveness of checkpoint inhibitors in 30% of patients.

JP7588074B2Active Publication Date: 2024-11-21SIRNAOMICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021538037
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-12-27
Filing Date
2019-12-24
Publication Date
2024-11-21
Estimated Expiration
2039-12-24

AI Technical Summary

Technical Problem

Existing immune checkpoint inhibitors, such as antibodies against PD-1 or PD-L1, only show a therapeutic response in approximately 30% of patients, and the mechanisms behind this variability are not fully understood, with elevated TGF-beta1 levels inhibiting T cell entry into tumors being a potential factor.

Method used

The use of small interfering RNA (siRNA) molecules targeting TGF-beta1 and Cox2, delivered via nanoparticles, to silence these genes in proximity to tumors, combined with immune checkpoint inhibitors, enhances the immune response against cancer cells.

Benefits of technology

This combination significantly increases the effectiveness of immune checkpoint inhibitors by allowing greater T cell entry into tumors, promoting a stronger immune response and reducing tumor growth, as demonstrated in liver, colon, pancreatic, and bladder cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007588074000001
    Figure 0007588074000001
  • Figure 0007588074000002
    Figure 0007588074000002
  • Figure 0007588074000003
    Figure 0007588074000003
Patent Text Reader

Abstract

The present invention provides certain pharmaceutical molecules and compositions, and methods of using them to treat cancer. The molecules are small interfering RNA (siRNA) molecules that inhibit TGF-beta 1 and Cox2 in humans and other mammals, and are used alone or in combination with immune checkpoint inhibitors to treat cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED PATENT APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 785,647, filed December 27, 2018, which is incorporated herein by reference in its entirety. Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated herein by reference in its entirety. The above ASCII copy, created on February 14, 2020, is named 4690_0016i_SL.txt and is 8,518 bytes in size.

[0002] The present invention relates to certain pharmaceutical molecules and compositions and their use for treating cancer, in particular the use of small interfering RNA (siRNA) molecules that inhibit TGF-beta 1 and Cox2, alone or in combination with immune checkpoint inhibitors, for treating cancer. [Background technology]

[0003] Recent studies have identified immune checkpoint inhibitors as important targets in the fight against cancer. Receptors, such as PD-1 (on the surface of T cells), can interact with ligands (e.g., PD-L1) on the surface of tumor cells, and this binding between these molecules results in a signal to the T cells that the tumor should not be destroyed. As a result, this signaling mechanism has been thoroughly studied to try and identify ways to block it and thus promote immune recognition of tumors, with the resulting increase in tumor killing that this generates.

[0004] Many checkpoints have been discovered, including CTLA4, Lag3, Tim3, PD-1 and PD-L1. For example, antibodies against PD1 or PD-L1 have been demonstrated to block the interaction between the PD-1 receptor and the PD-L1 ligand, which inhibits the "do not eat me" signal from tumor cells to T cells, which would otherwise prevent T cells from mounting a normal response against tumors and other foreign cells by releasing enzymes that kill the cells.

[0005] With the translation of these antibodies (pembrolizumab, Keytruda™, etc.) into the clinic, it has been found that treating patients with these agents can stimulate very strong immune responses in approximately 30% of patients, resulting in a long-lasting cure for these patients. However, the reason why this response was seen in only 30% of treated patients is not clearly understood, and therefore research has focused extensively on other pathways and signaling mechanisms that may be operative in inhibiting the immune response, as well as the ability of T cells to kill tumor cells.

[0006] RNA interference (RNAi) is a sequence-specific RNA degradation process that provides a relatively easy and straightforward way to knockdown or silence theoretically any gene that contains a homologous sequence. In naturally occurring RNAi, double-stranded RNA (dsRNA) is cleaved by the RNase III / helicase protein, Dicer, into small interfering RNA (siRNA) molecules, which are 19-27 nt dsRNAs with 2 nucleotide (nt) overhangs at the 3' end. The siRNAs are then incorporated into a multi-component ribonuclease called the RNA-induced silencing complex (RISC). One strand of the siRNA remains associated with the RISC and guides the complex towards a cognate RNA that has a sequence complementary to the guider ss-siRNA in the RISC. This siRNA-directed endonuclease digests the RNA, resulting in truncation and inactivation of the targeted RNA. Recent studies have demonstrated the utility of chemically synthesized 21-27 nt siRNAs to display RNAi effects in mammalian cells and have demonstrated that the thermodynamic stability of siRNA hybridization (at either the ends or the center) plays a central role in determining the function of the molecule. More detailed characterization of RISC, siRNA molecules, and RNAi is described in the scientific literature.

[0007] The usefulness of RNAi in downregulating mammalian cell gene expression has been successfully demonstrated in the laboratory by utilizing either chemically synthesized siRNA or endogenously expressed siRNA. Endogenous siRNA is first expressed as small hairpin RNA (shRNA) by an expression vector (plasmid or viral vector), and then processed by Dicer into functional siRNA.

[0008] In order to be active and to be able to silence target genes, siRNA can be delivered to cells where silencing must occur by transfection of these cells.One way to obtain siRNA delivery to these cells is to use nanoparticles that can carry siRNA and allow siRNA to be taken up across the outer cell membrane to gain access to the cytoplasm.The release of siRNA into the cytoplasm allows these moieties to interact with RISC complex, where antisense strand is separated from sense strand, the sense strand is degraded, and the antisense strand is used by RISC complex to scout the mRNA in the cell for sequences that have complementarity to antisense sequence.This allows the hybridization of the two sequences, and then the cleavage of mRNA occurs through the action of the enzyme Dicer.

[0009] mRNA provides a template for the translation of mRNA sequence into viable protein required by the cell. Cleavage of mRNA reduces the cell's ability to produce peptide or protein encoded by mRNA. Silencing of gene by siRNA can present a prolonged effect, depending on the balance between turnover and the rate of synthesis, amount of mRNA, and rate of degradation of mRNA and / or protein itself. siRNA has been shown to have a strong silencing effect on targeted genes, which can further result in a prolonged reduction (days to weeks) of protein production.

[0010] Elevated TGF-beta1 levels have been implicated in inhibiting T cell entry into areas adjacent to tumors [1-3].

[0011] For example, in tumors from patients with colon cancer [1, 2] or metastatic urothelial carcinoma treated with anti-PD-L1 antibodies (atezolizumab), the lack of response was associated with transforming growth factor beta (TGFβ) signaling in fibroblasts. Primarily, this was observed in tumors that showed exclusion of CD8+ T cells from the tumor parenchyma and accumulation of these T cells in the fibroblast- and collagen-rich peritumoral stroma, a phenotype common in patients with metastatic urothelial carcinoma. Coadministration of TGFβ-blocking antibodies with anti-PD-L1 antibodies reduced TGFβ signaling in stromal cells, which in turn allowed T cell entry into the center of the tumor, inducing antitumor immunity and tumor regression in this model [3].

[0012] [1] and [2] have focused on colon cancer, and [3] has shown efficacy in urothelial cancer, but no one has attempted to investigate the synergistic effect between TGFβ1 and PDL1 inhibition on immune response when both targets are simultaneously inhibited. We used polypeptide nanoparticles (PNPs) to deliver siRNA targeting TGFβ1 and siRNA targeting Cox2 to the liver to see if this effect would improve the efficacy of PDL1 antibodies in this disease. Delivery to endothelial cells as well as normal liver cells suggested that we were able to silence the two genes within the vicinity of the tumor. Summary of the Invention

[0013] Description of the invention The present invention relates to the use of small interfering RNA (siRNA) molecules that inhibit TGF-beta1 and Cox2 in a subject, alone or in combination with immune checkpoint inhibitors, to treat cancer in a subject.As used herein, the term "subject" refers to any mammal, including human.The subject may be an experimental animal, such as a rodent, ferret or non-human primate.Preferably, the subject is a human.

[0014] In one embodiment, the present invention relates to a method for killing cancer cells in a subject by administering a therapeutically effective amount of anti-TGF-beta 1 siRNA to the subject.In one aspect of this embodiment, anti-TGF-beta 1 siRNA is administered intravenously to the subject.In another aspect of this embodiment, anti-TGF-beta 1 siRNA is administered into the tumor in the subject.In yet another aspect of this embodiment, anti-TGF-beta 1 siRNA is administered close to the tumor or administered systemically in a vehicle that allows delivery to the tumor.

[0015] In another embodiment, the present invention relates to a method for treating cancer in a subject by administering a therapeutically effective amount of anti-TGF-beta 1 siRNA to the subject.In one aspect of this embodiment, anti-TGF-beta 1 siRNA is administered intravenously to the subject.In another aspect of this embodiment, anti-TGF-beta 1 siRNA is administered into the tumor in the subject.In yet another aspect of this embodiment, anti-TGF-beta 1 siRNA is administered close to the tumor or administered systemically in a vehicle that allows delivery to the tumor.

[0016] The cancer (and cancer cells) is any cancer that afflicts a subject. Such cancers include liver, colon, pancreas, lung and bladder cancer. Liver cancer can be primary liver cancer or cancer that has metastasized to the liver from another tissue. Primary liver cancer includes hepatocellular carcinoma and hepatoblastoma. Metastatic cancer includes colon and pancreatic cancer.

[0017] Anti-TGF-beta 1 siRNA molecules include the sequences identified in Table 1.

[0018] Table 1: Anti-TGF - Beta 1 siRNA sequence hmTF-25-1: sense 5'-r(GGAUCCACGAGCCCAAGGGCUACCA)-3' (SEQ ID NO:1) Antisense 5'-r(UGGUAGCCCUUGGGCUCGUGGAUCC)-3' (SEQ ID NO:2) hmTF-25-2: sense 5'-r(CCCAAGGGCUACCAUGCCAACUUCU)-3' (SEQ ID NO:3) Antisense 5'-r(AGAAGUUGGCAUGGUAGCCCUUGGG)-3' (SEQ ID NO:4) hmTF-25-3: sense 5'-r(GAGCCCAAGGGCUACCAUGCCAACU)-3' (SEQ ID NO:5) Antisense 5'-r(AGUUGGCAUGGUAGCCCUUGGGCUC)-3' SEQ ID NO:6 hmTF25-4: sense, 5'-r(GAUCCACGAGCCCAAGGGCUACCAU)-3' (SEQ ID NO:7) Antisense, 5'-r(AUGGUAGCCCUUGGGCUCGUGGAUC)-3' (SEQ ID NO:8) hmTF25-5: sense, 5'-r(CACGAGCCCAAGGGCUACCAUGCCA)-3' (SEQ ID NO:9) Antisense, 5'-r(UGGCAUGGUAGCCCUUGGGCUCGUG)-3' (SEQ ID NO:10) hmTF25-6: sense, 5'-r(GAGGUCACCCGCGUGCUAAUGGUGG)-3' SEQ ID NO:11 Antisense, 5'-r(CCACCAUUAGCACGCGGGUGACCUC)-3' (SEQ ID NO:12) hmTF25-7: sense, 5'-r(GUACAACAGCACCCGCGACCGGGUG)-3' (SEQ ID NO:13) Antisense, 5'-r(CACCCGGUCGCGGGUGCUGUUGUAC)-3' SEQ ID NO:14 hmTF25-8: sense, 5'-r(GUGGAUCCACGAGCCCAAGGGCUAC)-3' (SEQ ID NO:15) Antisense, 5'-r(GUAGCCCUUGGGCUCGUGGAUCCAC)-3' (SEQ ID NO:16)

[0019] In one embodiment, the anti-TGF-beta 1 siRNA has the following sequence: Sense: 5'-cccaagggcuaccaugccaacuucu-3' (SEQ ID NO:3) ;Antisense: 5'-agaaguuggcaugguagcccuuggg-3' (SEQ ID NO:4) Includes.

[0020] The anti-TGF-beta 1 siRNA is administered to the subject in a pharma- ceutically acceptable carrier. Such carriers include branched histidine-lysine polymers. In one embodiment of such polymers, the polymer has the formula (R)K(R)-K(R)-(R)K(X), where R = KHHHKHHHKHHHKHHHK. (SEQ ID NO:17) or R=KHHHKHHHHKHHHKHHK (SEQ ID NO:18) , X=C(O)NH2, K=Lysine and H=Histidine. Such polymers form nanoparticles with anti-TGF-beta 1 siRNA. The nanoparticles can be administered intravenously or intratumorally to a subject.

[0021] In another embodiment, the present invention relates to a method of killing cancer cells in a subject by administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor together with a therapeutically effective amount of an anti-TGF-beta 1 siRNA. In one aspect of this embodiment, administering the immune checkpoint inhibitor together with the anti-TGFbeta 1 siRNA increases the effectiveness of the anti-TGFbeta 1 siRNA.

[0022] In another embodiment, the present invention relates to a method of treating cancer in a subject by administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor together with a therapeutically effective amount of an anti-TGF-beta 1 siRNA. In one aspect of this embodiment, administering the immune checkpoint inhibitor together with the anti-TGFbeta 1 siRNA increases the efficacy of the anti-TGFbeta 1 siRNA.

[0023] As described above, the immune checkpoint inhibitors and anti-TGF-beta 1 siRNA are administered intravenously to the subject, administered into a tumor in the subject in close proximity to the tumor, or administered systemically in a vehicle that allows delivery to the tumor.

[0024] In one aspect of this embodiment, the immune checkpoint inhibitor is a monoclonal antibody that blocks the interaction between receptors, such as PD-1, PD-L1, CTLA4, Lag3 and Tim3, on mammalian cells, e.g., human cells, and ligands for these receptors. In a particular aspect, the monoclonal antibody is a monoclonal antibody against PD1 or PDL1. Examples of monoclonal antibodies include Atezoluzimab, Durvalumab, Nivolumab, Pembrolizumab and Ipilimumab.

[0025] In yet another aspect of this embodiment, the immune checkpoint inhibitor is a small molecule that blocks the interaction between receptors, such as PD-1, PD-L1, CTLA4, Lag3 and Tim3, on mammalian cells, e.g., human cells, and ligands for these receptors.In a particular aspect, the small molecule blocks the binding between PD1 and PDL1.BMS202 and similar ligands are examples of such small molecules.

[0026] In a further embodiment, the present invention relates to a method for killing cancer cells in a subject by administering to the subject a therapeutically effective amount of anti-Cox-2 siRNA together with a therapeutically effective amount of anti-TGF-beta 1 siRNA.In one aspect of this embodiment, the combination is administered intravenously to the subject.In another aspect of this embodiment, the combination is administered into the tumor in the subject.In yet another aspect of this embodiment, the combination is administered close to the tumor or administered systemically in a vehicle that allows delivery to the tumor.

[0027] In yet another embodiment, the present invention relates to a method for treating cancer in a subject by administering to the subject a therapeutically effective amount of anti-Cox-2 siRNA together with a therapeutically effective amount of anti-TGF-beta 1 siRNA.In one aspect of this embodiment, the combination is administered intravenously to the subject.In another aspect of this embodiment, the combination is administered into the tumor in the subject.In yet another aspect of this embodiment, the combination is administered close to the tumor or administered systemically in a vehicle that allows delivery to the tumor.

[0028] The anti-Cox2 siRNA molecules include the sequences identified in Table 2.

[0029] Table 2: Anti-Cox2 siRNA sequences hmCX-25-1: sense 5'-r(GGUCUGGUGCCUGGUCUGAUGAUGU)-3' (SEQ ID NO: 19) Antisense 5'-r(ACAUCAUCAGACCAGGCACCAGACC)-3' (SEQ ID NO:20) hmCX-25-2: sense 5'-r(GAGCACCAUUCUCCUUGAAAGGACU)-3' SEQ ID NO:21 Antisense 5'-r(AGUCCUUUCAAGGAGAAUGGUGCUC)-3' (SEQ ID NO:22) hmCX-25-3: sense 5'-r(CCUCAAUUCAGUCUCUCAUCUGCAA)-3' (SEQ ID NO:23) Antisense 5'-r(UUGCAGAUGAGAGACUGAAUUGAGG)-3' (SEQ ID NO:24) hmCX25-4: sense, 5'-r(GAUGUUUGCAUUCUUUGCCCAGCAC)-3' (SEQ ID NO:25) Antisense, 5'-r(GUGCUGGGCAAAGAAUGCAAACAUC)-3' SEQ ID NO:26 hmCX25-5: sense, 5'-r(GUCUUUGGUCUGGUGCCUGGUCUGA)-3' (SEQ ID NO:27) Antisense, 5'-r(UCAGACCAGGCACCAGACCAAAGAC)-3' (SEQ ID NO:28) hmCX25-6: sense, 5'-r(GUGCCUGGUCUGAUGAUGUAUGCCA)-3' (SEQ ID NO:29) Antisense, 5'-r(UGGCAUACAUCAUCAGACCAGGCAC)-3' (SEQ ID NO:30) hmCX25-7: sense, 5'-r(CACCAUUCUCCUUGAAAGGACUUAU)-3' SEQ ID NO:31 Antisense, 5'-r(AUAAGUCCUUUCAAGGAGAAUGGUG)-3' (SEQ ID NO:32) hmCX25-8: sense, 5'-r(CAAUUCAGUCUCUCAUCUGCAAUAA)-3' (SEQ ID NO:33) Antisense, 5'-r(UUAUUGCAGAUGAGAGACUGAAUUG)-3' SEQ ID NO:34

[0030] In one embodiment, the anti-Cox2 siRNA has the following sequence: Sense: 5'-ggucuggugccuggucugaugaugu-3' (SEQ ID NO: 19) ;Antisense: 5'-acaucaucagaccaggcaccagacc-3' (SEQ ID NO:20) Includes.

[0031] The anti-TGF-beta 1 siRNA and anti-Cox2 siRNA are administered in a pharma- ceutically acceptable carrier. Such carriers include branched histidine-lysine polymers. In one embodiment of such polymers, the polymer has the formula (R)K(R)-K(R)-(R)K(X), where R = KHHHKHHHKHHHKHHHK. (SEQ ID NO:17) or R=KHHHKHHHHKHHHKHHK (SEQ ID NO:18), X=C(O)NH2, K=Lysine, H=Histidine and N=Asparagine. Such polymers form nanoparticles with anti-TGF-beta 1 siRNA and anti-Cox2 siRNA. The nanoparticles can be administered intravenously or intratumorally to a subject.

[0032] As described above with respect to anti-TGF-beta 1 siRNA, the cancer (and cancer cells) targeted by the combination of anti-TGF-beta 1 siRNA and anti-Cox2 siRNA can be any cancer that afflicts a subject. Such cancers include liver, colon, pancreas, lung and bladder cancer. Liver cancer can be primary liver cancer or cancer that metastasizes to the liver from another tissue. Primary liver cancer includes hepatocellular carcinoma and hepatoblastoma. Metastatic cancer includes colon and pancreatic cancer.

[0033] In a further embodiment, the present invention relates to a method for killing cancer cells in a subject by administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor together with a therapeutically effective amount of an anti-TGF-beta 1 siRNA and a therapeutically effective amount of an anti-Cox2 siRNA.The cancer cells and cancers to which this method relates are any cancers that afflict the subject, including those described above.In one aspect of this embodiment, administering the immune checkpoint inhibitor together with the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA increases the effectiveness of any one of the siRNAs alone.

[0034] In yet another embodiment, the present invention relates to a method for treating cancer in a subject by administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor together with a therapeutically effective amount of an anti-TGF-beta 1 siRNA and a therapeutically effective amount of an anti-Cox2 siRNA.The cancer cells and cancers to which this method relates are any cancers that afflict the subject, including those described above.In one aspect of this embodiment, administering the immune checkpoint inhibitor together with the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA increases the effectiveness of any one of the siRNAs alone.

[0035] As described above, the immune checkpoint inhibitors, anti-TGF-beta 1 siRNA and anti-Cox2 siRNA are administered intravenously to the subject, administered into a tumor in the subject in close proximity to the tumor, or administered systemically in a vehicle that allows delivery to the tumor.

[0036] The immune checkpoint inhibitor administered with the combination of siRNA molecules is a monoclonal antibody or small molecule as described above, which can be administered before, after, or simultaneously with the combination of siRNA molecules.

[0037] The present invention relates to certain pharmaceutical compositions.In one embodiment, the composition comprises the anti-TGF-beta 1 siRNA described herein in a pharma- ceutically acceptable carrier described herein.

[0038] In another embodiment, the pharmaceutical composition is used in conjunction with an immune checkpoint inhibitor as described herein.Accordingly, this embodiment of the present invention relates to a combination of a therapeutic agent comprising an immune checkpoint inhibitor as described herein and a pharmaceutical composition comprising an anti-TGF-beta 1 siRNA in a pharma- ceutical acceptable carrier.

[0039] In yet another embodiment, the invention relates to a combination of a therapeutic agent comprising an immune checkpoint inhibitor, as described herein, with a pharmaceutical composition comprising an anti-TGF-beta 1 siRNA and an anti-Cox2 siRNA and a pharma- ceutical acceptable carrier.

[0040] The combination of therapeutic agents described herein is also useful for enhancing the antitumor effect of immune checkpoint inhibitors in subjects with cancer. A pharmaceutical composition comprising a therapeutically effective amount of anti-TGF-beta 1 siRNA and anti-Cox2 siRNA is administered to a subject together with a therapeutically effective amount of a checkpoint inhibitor. Anti-TGF-beta 1 siRNA reduces the subject's inflammatory response to cancer, allowing better infiltration of T cells and other immune cells into tumors. This also elicits a stronger immune response to cancer in the subject than the immune response elicited by checkpoint inhibitors alone. This response involves greater T cell activation and infiltration into cancer. Anti-Cox2 siRNA reduces the subject's inflammatory response to cancer and / or reduces the formation of exhausted T cells or regulatory T cells around the cancer.

[0041] The combination of therapeutic agents described herein is also useful for antigenically priming T cells in a subject to recognize and kill cancer cells, and for promoting T cell-mediated immunity against cancer in a subject.A therapeutically effective amount of the combination is administered to the subject.Cancer is as described herein.

[0042] In a particular embodiment, the present invention relates to a method for treating liver cancer in a subject by administering to the subject a therapeutically effective amount of the pharmaceutical composition of the present invention or the combination of therapeutic agents of the present invention.In one aspect of this embodiment, the liver cancer is primary liver cancer.In a particular aspect, the primary liver cancer is hepatocellular carcinoma or hepatoblastoma.In another aspect of this embodiment, the liver cancer is a cancer that metastasizes to the liver from another tissue in the subject's body.Such metastatic cancers include colon cancer and pancreatic cancer.In one aspect of this embodiment, the subject is a human.

[0043] In another specific embodiment, the present invention provides a method of killing hepatocellular carcinoma cells in a human, comprising administering to the human a therapeutically effective amount of a pharmaceutical composition comprising anti-TGF-beta 1 siRNA and anti-Cox2 siRNA in a pharma- ceutically acceptable carrier comprising a branched histidine-lysine polymer that forms nanoparticles with anti-TGF-beta 1 siRNA and anti-Cox2 siRNA, wherein the anti-TGF-beta 1 siRNA has the sequence: sense: 5'-cccaagggcuaccaugccaacuucu-3' (SEQ ID NO:3) ;Antisense: 5'-agaaguuggcaugguagcccuuggg-3' (SEQ ID NO:4) and the anti-Cox2 siRNA comprises the sequence: sense: 5'-ggucuggugccuggucugaugaugu-3' (SEQ ID NO: 19) ;Antisense: 5'-acaucaucagaccaggcaccagacc-3' (SEQ ID NO:20) The present invention relates to a method comprising the steps of:

[0044] In yet another specific embodiment, the present invention provides a method of killing hepatocellular carcinoma cells in a human, comprising administering to the human a therapeutically effective amount of an immune checkpoint inhibitor and an anti-TGF beta 1 siRNA in a pharma- ceutical acceptable carrier comprising a branched histidine-lysine polymer forming nanoparticles with anti-TGF-beta 1 siRNA and anti-Cox2 siRNA. - Administering a pharmaceutical composition comprising a beta 1 siRNA and an anti-Cox2 siRNA, wherein the anti-TGF-beta 1 siRNA has the sequence: sense: 5'-cccaagggcuaccaugccaacuucu-3' (SEQ ID NO:3) ;Antisense: 5'-agaaguuggcaugguagcccuuggg-3' (SEQ ID NO:4) and the anti-Cox2 siRNA comprises the sequence: sense: 5'-ggucuggugccuggucugaugaugu-3' (SEQ ID NO: 19) ;Antisense: 5'-acaucaucagaccaggcaccagacc-3' (SEQ ID NO:20)wherein the checkpoint inhibitor comprises a monoclonal antibody capable of binding to PD1 and PDL1 and blocking the interaction between PD1 and PDL1. Such monoclonal antibodies include atezolzimab, durvalumab, nivolumab, pembrolizumab and ipilimumab.

[0045] In a further specific embodiment, the present invention relates to a combination of a therapeutic comprising an immune checkpoint inhibitor and a pharmaceutical composition comprising an anti-TGF-beta 1 siRNA and an anti-Cox2 siRNA in a pharma- ceutically acceptable carrier, wherein the checkpoint inhibitor comprises a monoclonal antibody selected from the group consisting of atezolizimab, durvalumab, nivolumab, pembrolizumab and ipilimumab, and the anti-TGF-beta 1 siRNA has the sequence: sense: 5'-cccaagggcuaccaugccaacuucu-3' (SEQ ID NO:3) ;Antisense: 5'-agaaguuggcaugguagcccuuggg-3' (SEQ ID NO:4) and the anti-Cox2 siRNA comprises the sequence: sense: 5'-ggucuggugccuggucugaugaugu-3' (SEQ ID NO: 19) ;Antisense: 5'-acaucaucagaccaggcaccagacc-3' (SEQ ID NO:20) and the pharma- ceutically acceptable carrier comprises a branched histidine-lysine polymer that forms nanoparticles with the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA. In one aspect of this embodiment, the branched histidine-lysine polymer has the formula (R)K(R)-K(R)-(R)K(X), where R = KHHHKHHHKHHHKHHHK (SEQ ID NO:17) or KHHHKHHHKHHHHKHHHK (SEQ ID NO:18) , X=C(O)NH2, K=lysine, H=histidine and N=asparagine. [Brief description of the drawings]

[0046] [Figure 1]Figure 1 shows the localization of IV-administered STP707 within cells in the liver. AF647 fluorecent-labeled siRNA was formulated with HKP to form nanoparticles. Nanoparticles were administered to mice by IV injection (tail vein administration). At the time points noted in the figure, animals were euthanized, livers were excised, dissected, and dissociated cells were subjected to flow cytometry using labeled antibodies capable of discriminating between the different cell types indicated. Below each time point, the cell types are indicated from left to right: Kupffer cells (KC), dendritic cells (DC), liver sinusoidal wall endothelial cells (LSEC), hepatocytes, Ly6c high (inflammatory monocytes), Ly6c low, polymorphonuclear cells (PMN), lymphocytes, and stellate cells. The figure shows that hepatocytes, Kupffer cells, and LSEC cells are the first to take up STP707 at 1 hour. The stellate cell population in the liver is only 1.4% of the cell population. Flow cytometry showed some evidence of uptake, but the signal was too low, therefore we validated uptake in primary human astrocytes and demonstrated excellent uptake and gene silencing in these cells. [Diagram 2] Tumor burden was assessed by measuring light efflux from each animal using a luciferin substrate administered to anesthetized animals (measured using a digital imaging system). Animals were assigned to cohorts based on tumor normalization across all study groups. The figure shows the initial values ​​generated at the time of group assignment, demonstrating the uniformity of tumor size between cohorts before treatment began. [Diagram 3] Animal weight was monitored after each treatment, and the average weight across all animals in the cohort is shown. Data is plotted as % of initial weight before dosing. Sorafenib alone (red squares) induced little change in body weight. However, all other treatment schemes (STP707 alone or + anti-PDL1) were well tolerated, and no significant weight loss was observed in the treatment groups. [Figure 4]Tumor-associated bioluminescence (TABL) measurements were performed by administering luciferase substrate (luciferin) to anesthetized animals and then imaging the light produced using an IVIS live animal imaging system. Animals were administered treatment throughout the dosing phase (grey highlighted areas) and otherwise monitored without treatment at other times. Control (vehicle) treated animals showed rapid growth of tumors as determined by a larger light signal. Sorafenib and anti-PDL1 mAb treatments appeared to have a static effect on tumor growth over the dosing phase. STP707 alone (40 μg per injection, or approximately 2 mg / kg) or STP707 with anti-PDL1 mAb showed a dramatic reduction in tumor cells after 5-6 doses. Tumors were not visible in these treatment groups. [Diagram 5] FIG. 1 shows that uncontrolled tumor growth dramatically impacts animal survival in control (vehicle-treated) animals. 50% of untreated animals died or were euthanized as a result of increased tumor burden during the dosing phase of the experiment. With sorafenib, one animal was euthanized after 37 days. No animals died in any of the other treatment groups. [Figure 6] Data show that the control sample (PNP loaded with non-silencing (NS) siRNA) showed a dramatic increase in tumor cell proliferation as measured by flux readings from outside the animal using an IVIS imaging system. The PDL1 antibody showed a weak inhibitory effect on tumor growth. STP707 alone (1 mg / Kg) showed even greater inhibition of tumor growth than PDL1 Ab, and in the presence of anti-PDL1 mAb, STP707 completely abolished the tumors after 6 doses, suggesting some additivity of the effect with the antibody. [Figure 7]STP707 was administered three times at 1 mg / kg to animals bearing syngeneic orthotopic HCC tumors, and then the liver was excised, sectioned, and stained (H&E) to show the location and size of the tumor. Note the dramatic reduction in tumor size when STP707 was administered over this short period of time. In the areas indicated by the white squares, the amount of CD4+ and CD8+ T cells was quantified by staining and counting the stained spots. These areas are enlarged on the right side of each figure, and it can be clearly seen that STP707 treatment produced a dramatic increase in the number of CD4+ and CD8+ T cells present within the liver-tumor margin, suggesting that STP707 treatment allows greater T cell infiltration into the tumor. [Figure 8] Using images similar to those shown in Figure 7, T cells were quantified in various segments measured either away from the tumor margin, toward the tumor, or toward the liver. Within each segment (50 μm thick), the number of T cells was quantified and plotted on the graph shown. STP707 treatment with anti-PDL1 Ab showed a 2-fold increase in CD8+ T cells at a depth of 500 μm into the tumor compared to vehicle treatment alone. This also showed an increase in CD8+ T cells in the liver close to the tumor, suggesting a possible recruitment of T cells induced by the reduction of the TGF-beta "wall" surrounding the tumor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0047] definition Liver cancer is any primary cancer in the liver, i.e., that begins in the liver; or any secondary cancer in the liver, i.e., that metastasizes to the liver from another tissue in the mammalian body. An example of primary liver cancer is hepatocellular carcinoma. An example of secondary liver cancer is colon cancer.

[0048] Cancer is any malignant tumor.

[0049] A malignant tumor is a mass of neoplastic cells.

[0050] Treating / treatment is killing some or all of the cancer cells, reducing the size of the cancer, inhibiting the growth of the cancer, or reducing the rate of growth of the cancer in a subject.

[0051] Anti-TGF-beta 1 siRNA is a siRNA molecule that reduces or prevents the expression of the gene encoding the synthesis of the TGF-beta 1 protein in mammalian cells.

[0052] Anti-Cox2 siRNA is a siRNA molecule that reduces or prevents the expression of the gene encoding the synthesis of the Cox2 protein in mammalian cells.

[0053] siRNA molecules are double-stranded oligonucleotides, which are short double-stranded polynucleotides that interfere with the expression of genes in cells after the molecules are introduced into cells.For example, they target and bind to complementary nucleotide sequences in single-stranded target RNA molecules.siRNA molecules are chemically synthesized or otherwise constructed by techniques known to those skilled in the art.Such techniques are described in U.S. Patent Nos. 5,898,031, 6,107,094, 6,506,559, 7,056,704 and European Patent Nos. 1214945 and 1230375, which are incorporated herein by reference in their entirety.By convention in the art, when an siRNA molecule is identified by a specific nucleotide sequence, this sequence refers to the sense strand of the double-stranded molecule.One or more of the ribonucleotides that make up the molecule can be chemically modified by techniques known in the art.In addition to being modified at one or more levels of its individual nucleotides, the backbone of the oligonucleotide can be modified. Further modifications include the use of small molecules (eg, sugar molecules), amino acids, peptides, cholesterol, and other macromolecules for conjugation onto the siRNA molecule.

[0054] Branched histidine-lysine polymers are peptides consisting of histidine and lysine amino acids. By synthesizing multiple amino acids from a common lysine core, the peptide is composed of four arms or branches. Such polymers are described in U.S. Patent Nos. 7,070,807(B2) issued on July 4, 2006, 7,163,695(B2) issued on January 6, 2007, and 7,772,201(B2) issued on August 10, 2010, which are incorporated herein by reference in their entirety.

[0055] Immune checkpoint inhibitors are drugs that block certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These checkpoint proteins help keep the immune response in check and can keep T cells from killing cancer cells. When these checkpoint proteins are blocked, the "brakes" on the immune system are released and T cells can better kill cancer cells. Examples of checkpoint proteins found on T cells or cancer cells include PD-1 / PD-L1 and CTLA-4 / B7-1 / B7-2.

[0056] Proximal to a cancer means in tissues or cells near or surrounding a tumor or a set of tumor cells.

[0057] By enhancing the anti-tumor effect is meant providing a greater reduction in the rate of proliferation of tumor cells, a greater effect in killing tumor cells and / or in reducing tumor mass, and ultimately producing a better therapeutic effect by extending the life span of tumor-bearing subjects. Such effects can be mediated by direct effects on the tumor cells themselves, or by increasing the activity of T cells, or by mechanisms by which T cells are activated to gain better access to tumor cells and / or promote a stronger immune response against tumors, with or without an increase in their ability to recognize tumor cells even after initial treatment.

[0058] The following examples illustrate certain aspects of the present invention and should not be construed as limiting its scope. EXAMPLES

[0059] Experimental Results STP707 consists of two siRNAs (targeting the TGF-beta 1 gene and the Cox2 gene) protected by a polypeptide delivery nanoparticle consisting of the branched polypeptide HKP (histidine lysine polymer). STP707 is described in U.S. Patent No. 9,642,873 (B2) dated May 9, 2017 and U.S. Reissue Patent No. 46,873 dated May 29, 2018, the disclosures of which are incorporated herein by reference in their entirety.

[0060] Using branched polypeptide nanoparticles (HKPs) composed of histidine and lysine amino acids, we have demonstrated that IV injection allows nanoparticles to be taken up by cells in the liver with higher efficiency. Using flow cytometry to measure the uptake of fluorescently tagged siRNA from nanoparticles, we have demonstrated delivery to specific cell types in the liver, including stellate cells, LSEC cells, and hepatocytes as well as Kupffer cells (Figure 1). Therefore, this suggests that we can obtain very good delivery efficiency of siRNA to these cells in the liver, and thus silence the target of interest in these cells.

[0061] We tested STP707 as monotherapy and in combination with an anti-PD-L1 monoclonal antibody (mAb) (anti-PD-L1 monoclonal Ab clone 10F.9G2 from BioXcell, West Lebanon, NH 03784) in an orthotopic mouse hepatocellular carcinoma model using a bioluminescent variant of the Hepa 1-6 cell line to allow monitoring of tumor burden over time.

[0062] We used an orthotopic transplantation model in which HCC liver cancer tumor cells (Hepa 1-6 cells) were surgically implanted into the organ from which they were derived (the liver). A mouse liver cancer cell line was modified to express luciferase (Hepa 1-6-Lux). Then, upon addition of the substrate to the animals, the extent of tumor growth in the liver of these animals could be monitored using a luminescence detection system. This allows for the measurement of tumor growth in a non-invasive manner that is not harmful to the animals. We used this method to monitor the rate of tumor growth. We examined the rate of growth in the absence of any treatment (control group) using the ultimate standard of care for hepatocellular carcinoma treatment in humans (sorafenib - a kinase inhibitor; 50 mg / Kg administered once a day) and a validated mouse anti-PDL1 antibody (5 mg / Kg administered twice a week) that was shown to inhibit tumor growth in animals bearing orthotopic Hepa1-6 tumors.

[0063] The inventors demonstrated that siRNA (STP707) shown to inhibit TGF-beta and Cox2 was delivered using HKP peptide nanoparticles (40 μ g or 20 μ The effects of STP707 administered IV BIW at a dose of 1000 mg / kg were also compared. We also analyzed the effect of STP707 when administered together with an anti-PDL1 antibody.

[0064] We tested STP707 for efficacy in treating HCC using a syngeneic orthotopic mouse hepatocellular carcinoma model that employs a bioluminescent variant of the Hepa 1-6 cell line to allow monitoring of tumor burden over time.

[0065] Experiments were performed using C57BL / 6J mouse strain from Charles River labs.

[0066] Vehicle (HKP+non-silencing siRNA; control) or STP707 were both administered intravenously (iv).

[0067] Eight animals were randomly assigned to each treatment group, which were as follows: 1. Excipients only 2. Sorafenib (50mg / Kg) po, QD 3. Anti-PD-L1 (5mg / Kg), i.p., biw 4. Anti-PD-L1 (5mg / Kg), ip, BIW+20 μ g STP707 / Injection iv BIW 5. Anti-PD-L1 (5mg / Kg), ip, BIW+40 μ g STP707 / Injection iv BIW 6.40 μ g STP707 / injection iv BIW alone

[0068] Animals were randomized at the beginning of the experiment based on weight, which provided a very similar weight distribution among the selected animals within each group as shown in FIG.

[0069] Animal body weights were measured daily during the dosing phase of the efficacy study. The average body weights of each group were plotted (Figure 3). Sorafenib alone induced slight changes in body weight. However, all other treatment schemes (STP707 alone or + anti-PDL1) were well tolerated and no significant weight loss was observed in the treatment groups.

[0070] Tumor growth was monitored by bioluminescence imaging and reflected by tumor-associated bioluminescence (TABL) quantification. TABL was plotted by study days and shown in Figure 4.

[0071] Upon completion of the scheduled dosing phase, tumor growth was monitored for Groups 2 through 6. No tumor regrowth was observed prior to the last day of the study (day 50), suggesting that the treatment was highly effective in inhibiting tumor growth and preventing regrowth, suggesting a significant effect on tumor survival.

[0072] The efficacy of the combination therapy was further highlighted by survival analysis (using humane surrogate endpoints) for all mice in the study (Figure 5). The endpoint for humane termination was defined as either the time when the tumor reached maximum acceptable size or when the tumor exhibited adverse clinical signs. All treatment regimens produced statistically significantly improved survival as demonstrated by the log-rank (Mantel-Cox) test (p=0.0001) and Gehan-Breslow-Wilcoxon test (p=0.0002). No differences in survival were observed between treatment groups.

[0073] To verify the results obtained above, we repeated the study using a lower dose of STP707 (1 mg / kg) (Figure 6).

[0074] The data provided support the observation that STP707 exhibited a single agent effect on tumors - attenuating their growth compared to the control (untreated) cohort. The STP707 group showed better efficacy than the antibody group (PDL1) alone.

[0075] In this study, STP707 showed better single-agent activity than the anti-PDL1 antibody alone, but combining STP707 with the antibody treatment reduced tumors to undetectable levels after four doses.

[0076] Since there were no evident tumors in any of the STP707 treatment groups, we repeated the study but using only 3 doses of STP707 at 1 mg / Kg. After the third dose, animals were euthanized and livers were removed, sectioned, and stained for CD4+ and CD8+ T cells using immunohistochemistry.

[0077] Even in these reduced dose studies, we see dramatic differences between untreated (control) and STP707-treated samples in terms of overall tumor size: in untreated animals, tumors are almost entirely the size of the liver, whereas in STP707 samples, tumors are significantly reduced (Figure 7).

[0078] Furthermore, IHC staining for CD4+ and CD8+ T cells demonstrated a dramatic increase in these T cells infiltrating the tumors in STP707-treated samples (Figures 7 and 8).

[0079] Image analysis was performed to quantify CD4+ and CD8+ T cells in the margin between the tumor and liver as indicated by colored lines in the tumor samples. These lines were drawn at a distance of 50 um away from the tumor margin - either into the tumor, or away from the tumor but out towards the liver. Image analysis counted all CD8+ T cells in each 50 um segment and the data was plotted as shown in FIG. 8.

[0080] STP707 treatment together with anti-PDL1 Ab showed a 2-fold increase in CD8+ T cells 500 um into the tumor, as well as an increase in CD8+ T cells in the liver close to the tumor - suggesting possible recruitment of T cells induced by the lowering of the TGF-beta "wall" surrounding the tumor.

[0081] conclusion The primary objective of this study was to determine the tolerability and efficacy of STP707 (HKP polypeptide nanoparticles containing siRNA against TGFbeta1 and Cox2) as monotherapy and in combination with anti-PD-L1 in an orthotopic mouse hepatocellular carcinoma model using a bioluminescent variant of the Hepa 1-6 cell line.

[0082] All treatment regimens were well tolerated at the doses and formulations tested; no adverse clinical signs or weight loss were noted in any of the treatment groups.

[0083] All treatment regimens produced statistically significant reduced tumor growth when compared to controls. However, STP707 monotherapy (2mg / kg) resulted in reduced tumor growth, which was also observed when combined with anti-PDL1 Ab. Reducing the dose of STP707 to 1mg / Kg demonstrated a lower effect of STP707 alone, but here, additivity with anti-PDL1 Ab was more evident.

[0084] Anti-PD-L1 5mg / kg and STP705 (20 per injection) μ g (1 mg / kg) appeared to be more effective than STP705 monotherapy, which was more effective than anti-PD-L1 5 mg / kg.

[0085] Our results show that STP707 enhances the effect of anti-PDL1 antibody even after 2+ weeks of drug withdrawal, resulting in a dramatic reduction in tumor viability without tumor cell recurrence.The fact that we have demonstrated delivery to the liver with this formulation given IV suggests that we can use this regimen to treat tumors carried in the liver.This includes any tumors that naturally reside in the liver (hepatoblastoma or hepatocellular carcinoma (HCC)) or tumors that metastasize to the liver (e.g. colon cancer).

[0086] Furthermore, in previous studies, the inventors have demonstrated the ability to reduce gene expression for these two gene targets when the product is administered by injection (e.g., intradermal).This suggests that the inventors can obtain the same therapeutic benefit of promoting immune response against tumors when the product is administered via injection in close proximity to the tumor.This could be used for dermal cancers (e.g., non-melanoma skin cancers or melanoma tumors in the skin) or in tumors in other organs where material can be injected near the tumor site to promote the same effect.

[0087] References [1] Liu et al., Cancer Cell Int (2015) 15:106~112 “Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity” [2] Zelenay et al., Cell (2015) 162:1257~1270 “Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity” [3] Mariathasan et al., Nature (2018) 554;544~548 “TGFβ attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells”

[0088] All publications identified herein, including issued patents and published patent applications, and all database entries identified by URL address or accession number, are hereby incorporated by reference in their entirety.

[0089] While the invention has been described in relation to certain specific embodiments thereof, and numerous details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to further embodiments, and that certain details described herein may be varied without departing from the underlying principles of the invention.

Claims

1. A medicine for treating cancer, comprising: sense: 5'-cccaagggcuaccaugccaacuucu-3'; antisense: 5'-agaaguuggcaugguagcccuugggg-3', The anti-TGF-beta 1 siRNA is administered together with the anti-Cox2 siRNA, the anti-Cox2 siRNA having the sequences: sense: 5'-ggucuggugccuggucugaugaugu-3'; antisense: 5'-acaucaucagaccaggcaccagacc-3'; Medicine.

2. Anti-TGF-beta 1 siRNA and anti-Cox2 siRNA are administered intravenously; or The pharmaceutical composition of claim 1 , which is administered into or adjacent to a cancer malignancy.

3. The pharmaceutical composition according to claim 1 or 2, wherein the cancer is selected from the group consisting of liver cancer, colon cancer, pancreatic cancer, lung cancer and bladder cancer.

4. The pharmaceutical composition described in claim 3, wherein the cancer is liver cancer.

5. The cancer is a primary liver cancer selected from the group consisting of hepatocellular carcinoma and hepatoblastoma, or A cancer that has metastasized to the liver from another tissue, selected from the group consisting of colon cancer and pancreatic cancer; The pharmaceutical composition according to claim 4.

6. The method of any one of claims 1 to 5, wherein the anti-TGF-beta 1 siRNA is administered in a pharma- ceutically acceptable carrier comprising a branched histidine-lysine polymer.

7. The pharmaceutical of claim 6, wherein the branched histidine-lysine polymer has the formula (R)K(R)-K(R)-(R)K(X), where R=KHHHKHHHKHHHKHHHK or R=KHHHKHHHKHHHHKHHHKHHHK, X=C(O)NH2, K=lysine and H=histidine.

8. The pharmaceutical of claim 6 or 7, wherein the branched histidine-lysine polymer forms nanoparticles together with the anti-TGF-beta 1 siRNA.

9. The method of any one of claims 1 to 8, wherein the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA are administered in a pharma- ceutically acceptable carrier comprising a branched histidine-lysine polymer.

10. The pharmaceutical of claim 9, wherein the branched histidine-lysine polymer has the formula (R)K(R)-K(R)-(R)K(X), where R=KHHHKHHHKHHHKHHHK or R=KHHHKHHHKHHHHKHHHKHHHK, X=C(O)NH2, K=lysine and H=histidine.

11. The branched histidine-lysine polymer forms nanoparticles with anti-TGF-beta 1 siRNA and anti-Cox2 siRNA. The pharmaceutical composition according to claim 9 or 10.

12. The pharmaceutical composition of any one of claims 1 to 11, wherein the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA are administered together with an immune checkpoint inhibitor.

13. the immune checkpoint inhibitor comprises a monoclonal antibody that blocks the interaction between a cell surface receptor selected from the group consisting of PD-1, PD-L1, CTLA4, Lag3, and Tim3 and a ligand for these receptors; or The pharmaceutical agent of claim 12, wherein the immune checkpoint inhibitor comprises a small molecule that blocks an interaction between a cell surface receptor selected from the group consisting of PD-1, PD-L1, CTLA4, Lag3 and Tim3 and a ligand for these receptors.

14. The pharmaceutical described in claim 13, wherein the monoclonal antibody is a monoclonal antibody against PD1 or PDL1.

15. The pharmaceutical described in claim 14, wherein the monoclonal antibody is selected from the group consisting of atezolizumab, durvalumab, nivolumab, pembrolizumab and ipilimumab.

16. The pharmaceutical agent described in claim 13, wherein the small molecule blocks the binding between PD1 and PDL1.

17. The pharmaceutical described in claim 16, wherein the small molecule is selected from the group consisting of BMS202 and similar ligands.

18. A pharmaceutical composition for treating cancer in combination with an immune checkpoint inhibitor, the pharmaceutical composition comprising an anti-TGF-beta 1 siRNA and an anti-Cox2 siRNA in a pharma- ceutical acceptable carrier; anti-TGF-beta 1 siRNA has the sequence: sense: 5'-cccaagggcuaccaugccaacuucu-3'; anti-sense: 5'-agaaguuggcaugguagcccuuggg-3'; anti-Cox2 siRNA has the sequence: sense: 5'-ggucuggugccuggucugaugaugu-3'; anti-sense: 5'-acaucaucagaccaggcaccagacc-3'; Pharmaceutical compositions.

19. The pharmaceutical composition of claim 18, wherein the pharma- ceutically acceptable carrier comprises a branched histidine-lysine polymer that forms nanoparticles together with the anti-TGF-beta 1 siRNA and the anti-Cox2 siRNA.

20. The branched histidine-lysine polymer has the formula (R)K(R)-K(R)-(R)K(X), where R=KHHHKHHHKHHHKHHHK or R=KHHHKHHHKHHHHKHHHKHHHK, X=C(O)NH2, K=lysine and H=histidine.

20. The pharmaceutical composition of claim 19.

21. the immune checkpoint inhibitor comprises a monoclonal antibody that blocks the interaction between a cell surface receptor selected from the group consisting of PD-1, PD-L1, CTLA4, Lag3, and Tim3 and a ligand for these receptors; or The immune checkpoint inhibitor comprises a small molecule that blocks the interaction between a cell surface receptor selected from the group consisting of PD-1, PD-L1, CTLA4, Lag3, and Tim3 and a ligand for these receptors.

21. A pharmaceutical composition according to any one of claims 18 to 20.

22. The pharmaceutical composition of claim 21, wherein the monoclonal antibody binds to PD1 or PDL1.

23. The pharmaceutical composition of claim 22, wherein the monoclonal antibody is selected from the group consisting of atezolizumab, durvalumab, nivolumab, pembrolizumab and ipilimumab.

24. The pharmaceutical composition of claim 21, wherein the small molecule inhibits binding between PD1 and PDL1.

25. The pharmaceutical composition described in claim 24, wherein the small molecule is selected from the group consisting of BMS202 and similar structures.

26. 26. The pharmaceutical composition of any one of claims 18 to 25, wherein the cancer is selected from the group consisting of liver cancer, colon cancer, pancreatic cancer, lung cancer and bladder cancer.

27. ​​The pharmaceutical composition described in claim 26, wherein the cancer is liver cancer.

28. The cancer is a primary liver cancer selected from the group consisting of hepatocellular carcinoma and hepatoblastoma, or A cancer that has metastasized to the liver from another tissue, selected from the group consisting of colon cancer and pancreatic cancer; 28. The pharmaceutical composition of claim 27.

29. 29. The pharmaceutical composition of any one of claims 18 to 28, wherein the cancer is hepatocellular carcinoma in a human, the anti-TGF-beta 1 siRNA has the sequence: sense: 5'-cccaagggcuaccaugccaacuucu-3'; antisense: 5'-agaaguuggcaugguagcccuuggg-3', the anti-Cox2 siRNA has the sequence: sense: 5'-ggucuggugccuggucugaugaugu-3'; antisense: 5'-acaucaucagaccaggcaccagacc-3', and the checkpoint inhibitor is selected from the group consisting of atezolzimab, durvalumab, nivolumab, pembrolizumab and ipilimumab.

Citation Information

Patent Citations

  • Combinational therapeutics for treatment of prostate cancer using epoxy encapsulated magnetic particles and RNAI medicine

    WO2009104051A2

  • COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS

    WO2009151539A1

  • Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application

    WO2011140285A2

  • Gemcitabine derivatives for cancer therapy

    WO2018175323A1